title: Sirolimus-eluting versus paclitaxel-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: a combined RESEARCH and T-SEARCH long-term analysis.
abstract: OBJECTIVE
  The purpose of this study was to investigate the long-term clinical and angiographic profile of sirolimus-eluting stent (SES) versus paclitaxel-eluting stent (PES) in patients undergoing percutaneous intervention for left main (LM) coronary disease.
  
  
  BACKGROUND
  The long-term clinical and angiographic impact of SES as opposed to PES implantation in this subset of patients is unknown.
  
  
  METHODS
  From April 2002 to March 2004, 110 patients underwent percutaneous intervention for LM stenosis at our institution; 55 patients were treated with SES and 55 with PES. The two groups were well balanced for all baseline characteristics.
  
  
  RESULTS
  At a median follow-up of 660 days (range 428 to 885), the cumulative incidence of major adverse cardiovascular events was similar (25% in the SES group vs. 29%, in the PES group; hazard ratio 0.88 [95% confidence interval 0.43 to 1.82]; p = 0.74), reflecting similarities in both the composite death/myocardial infarction (16% in the SES group and 18% in the PES group) and target vessel revascularization (9% in the SES group and 11% in the PES group). Angiographic in-stent late loss (mm), evaluated in 73% of the SES group and in 77% of the PES group, was 0.32 +/- 74 in the main and 0.36 +/- 0.59 in the side branch in the SES group vs. 0.46 +/- 0.57 (p = 0.36) and 0.52 +/- 0.42 (p = 0.41) in the PES group, respectively.
  
  
  CONCLUSIONS
  In consecutive patients undergoing percutaneous LM intervention, PES may perform closely to SES both in terms of angiographic and long-term clinical outcome.
authors.affiliation: Erasmus Medical Center, Thoraxcenter, Rotterdam, The Netherlands.
authors.forename: Marco
authors.initials: M
authors.lastname: Valgimigli
authors.forename: Patrizia
authors.initials: P
authors.lastname: Malagutti
authors.forename: Jiro
authors.initials: J
authors.lastname: Aoki
authors.forename: Héctor M
authors.initials: HM
authors.lastname: Garcia-Garcia
authors.forename: Gaston A
authors.initials: GA
authors.lastname: Rodriguez Granillo
authors.forename: Carlos A G
authors.initials: CA
authors.lastname: van Mieghem
authors.forename: Jurgen M
authors.initials: JM
authors.lastname: Ligthart
authors.forename: Andrew T L
authors.initials: AT
authors.lastname: Ong
authors.forename: George
authors.initials: G
authors.lastname: Sianos
authors.forename: Evelyn
authors.initials: E
authors.lastname: Regar
authors.forename: Ron T
authors.initials: RT
authors.lastname: Van Domburg
authors.forename: Pim
authors.initials: P
authors.lastname: De Feyter
authors.forename: Peter
authors.initials: P
authors.lastname: de Jaegere
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D020099:Coated Materials, Biocompatible; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000628:therapy*; D005500:Follow-Up Studies; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage*; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents
chemical_list: D020099:Coated Materials, Biocompatible; D017239:Paclitaxel; D020123:Sirolimus